vip receptor vipr antagonist  (Tocris)

Journal: bioRxiv

Article Title: Master clock-thalamic-prefrontal circuit controls circadian social priority

doi: 10.64898/2025.12.05.691743

Figure Lengend Snippet: ( A to B ) Schematics for viral delivery (A) and an example image showing viral expression and optic fiber placement (B). ( C ) Experimental scheme of VIPR activity recording in freely moving animals. ( D to E ) Heatmap visualization of VIPR activity (D) and quantification of normalized VIPR activity (E) across two circadian timepoints. ( F ) Schematics for viral delivery and acute slice section for electrophysiological recording. (G) An example image showing Vipr2-expressing neuron with puff pipette. (H) Representative voltage-clamp trace showing a depolarizing response evoked by VIP agonist puff. Black bar indicates the timing of puff application. (I) Heatmap visualization of firing rates computed in cells that exhibited spontaneous EPSPs. Firing rate was calculated using a 500-ms sliding window. Top: aCSF puff (control); Bottom: VIP agonist puff. (J) The average Vm during the 2-second baseline period (Before), compared to the peak depolarization following the drug infusion. For (E), unpaired t-test; for (J), paired t-test was performed. Data are presented as mean ± SEM. ** P < 0.01.

Article Snippet: VIP receptor (VIPR) antagonist ([D-p-Cl-Phe 6 ,Leu 17 ]-VIP; #3054, Tocris), VIPR1 selective antagonist (PG 97-269; Bachem), and VIPR2 selective antagonist (PG 99-465; Bachem) were prepared in artificial cerebrospinal fluid (aCSF; #35-252, Tocris) in 1 mM concentration.

Techniques: Expressing, Activity Assay, Transferring, Control

Journal: bioRxiv

Article Title: Master clock-thalamic-prefrontal circuit controls circadian social priority

doi: 10.64898/2025.12.05.691743

Figure Lengend Snippet: ( A to B ) Schematics for cannula implantation (A) and an example image showing cannula placement (B). ( C ) Experimental scheme of social priority assay with systematic infusion of various pharmacological agents for VIP signaling. ( D ) Representative heatmap visualization of subject mice during social priority assay with pharmacological inhibition. ( E to H ) Quantification of investigation index (E), transition index (F), total interaction (G), and total distance moved (H) during social priority assay with pharmacological inhibition. ( I to J ) Schematics for viral delivery (I) and an example image showing viral expression (J). ( K ) Experimental scheme of social priority assay with or without genetic ablation of Vipr2 in RE. ( L ) Representative heatmap visualization of subject mice during social priority assay with or without genetic ablation of Vipr2 in RE. ( M to P ) Quantification of investigation index (M), transition index (N), total interaction (O), and total distance moved (P) during social priority assay with or without genetic ablation of Vipr2 in RE. n = 11, 9, 9, 10 for aCSF, VIPR, VIPR1, and VIPR2 antagonist treatment groups in (E to H). For (E), (G), (H), (M), (O), and (P), Two-way mixed ANOVA test followed by pairwise paired t-test and pairwise independent-sample t-test or non-parametric Two-way mixed ANOVA test followed by pairwise Wilcoxon Signed-Rank test and pairwise Wilcoxon Rank-Sum test; for (F), One-way ANOVA test followed by Tukey’s HSD test; for (N), unpaired t-test was performed. Each dot represents an individual animal. Each line represents a repeated experiment within individual animal. Data are presented as mean ± SEM. *** P < 0.001; ** P < 0.01; * P < 0.05.

Article Snippet: VIP receptor (VIPR) antagonist ([D-p-Cl-Phe 6 ,Leu 17 ]-VIP; #3054, Tocris), VIPR1 selective antagonist (PG 97-269; Bachem), and VIPR2 selective antagonist (PG 99-465; Bachem) were prepared in artificial cerebrospinal fluid (aCSF; #35-252, Tocris) in 1 mM concentration.

Techniques: Inhibition, Expressing

Journal: Cell reports

Article Title: The C9ORF72 repeat expansion alters neurodevelopment

doi: 10.1016/j.celrep.2023.112983

Figure Lengend Snippet: (A) Representative images of brains of 2-month-old mice exposed to vehicle or 2 μg/g VIP antagonist from E9.5–E11.5. (B) Quantification of brain mass in 2-month-old mice that were treated with vehicle or VIP antagonist from E9.5–E11.5. Each data point represents the brain mass of one mouse (n = 9 vehicle and n = 8 VIP antagonist). Mean ± SEM. Unpaired t test. (C and D) Representative images (C) and quantification (D) of cortical thickness in E18.5 control and C9ORF72 -BAC embryos treated with vehicle or 2 μg/g VIP antagonist using immunohistochemistry. Each data point represents the average cortical thickness in one embryo (n = 3 control and 3 C9ORF72 -BAC embryos). The average cortical thickness was determined by measuring the width from layer 1 to layer 6 across 3 different 16-mm sections beginning at approximately bregma + 3.51. Mean ± SEM. One-way ANOVA. Scale bars, 1 mm. (E) Quantification of time to fall in a hanging wire test for 2-month-old control and C9ORF72 -BAC mice treated with vehicle or VIP antagonist from E9.5–E11.5. Each data point represents the average time to fall for one mouse. Control + vehicle, n = 11 mice; control + VIP antagonist, n = 10 mice; C9ORF72 -BAC + vehicle, n = 10 mice; C9ORF72 -BAC + VIP antagonist, n = 16 mice. Mean ± SEM. Kruskal-Wallis test. (F) Quantification of total distance traveled during an open field test for 2-month-old control and C9ORF72 -BAC mice treated with vehicle or VIP antagonist from E9.5–E11.5. Each data point represents the total distance traveled for one mouse. Control + vehicle, n = 11 mice; control + VIP antagonist, n = 10 mice; C9ORF72 -BAC + vehicle, n = 10 mice; C9ORF72 -BAC + VIP antagonist, n = 16 mice. Mean ± SEM. two-way ANOVA.

Article Snippet: Pregnant dams were administered intraperitoneal (IP) injections of 2 μg/g body weight of the VIP receptor antagonist compound (Tocris, cat. no. 3054) once a day at E9.5, E10.5, and E11.5.

Techniques: Control, Immunohistochemistry